CRL · CIK 0001100682
What Charles River Laboratories International, Inc. told the SEC could break it.
Nearly everything Charles River flagged traces back to one fragile dependency: its supply of large research models, especially non-human primates, which comes from a limited set of international sources. That concentration shows up across the register — China's export restrictions on many animal species have constrained a once-significant source, a U.S. investigation into Cambodia-sourced non-human primates led to a $27 million inventory write-down, and significant tariffs remain in effect with the very countries it leans on for supply, including Vietnam, Mauritius, Cambodia and China. Any interruption to that narrow supply chain, the company warns, can hurt product availability, margins and operations.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- non-human primates (NHPs) / large research models — limited international supplyhigh
Several CRL offerings, including its NHP supply, depend on a limited international source of supply; disruptions from colony health, export/import restrictions, embargoes and tariffs can adversely affect the business.
“Several of our product and service offerings, including our non-human primate supply, are dependent on a limited source of supply that, when interrupted, adversely affects our business. We depend on a limited international source of supply for certain products, such as large research models, including NHPs.”
SEC filing →As of 2026
Geographic concentration
- China export restrictions on research modelsmedium
China previously supplied a significant portion of certain critical large research models, which have been subject to geographic export restrictions on many animal species since the start of the COVID-19 pandemic, constraining CRL's supply.
“Second, China previously supplied a significant portion of certain critical large research models, which have been subject to geographic export restrictions applicable to many animal species since the beginning of the COVID-19 pandemic.”
Litigation
- Cambodia-sourced non-human primate mattermedium
CRL recorded a $27 million inventory write-down tied to the February 16, 2023 Cambodia-sourced non-human primate matter (the U.S. investigation into NHP imports from Cambodia).
“The inventory balance as of December 28, 2024 is net of a $ 27 million inventory write down associated with the carrying value of inventory associated with the February 16, 2023, Cambodia-sourced non-human primate matter.”
SEC filing →As of 2026
Regulatory & policy
- tariffs on NHP-supply countries (Vietnam, Mauritius, Cambodia, China)medium
Significant tariffs remain in effect between the U.S. and countries from which CRL obtains significant supply — Vietnam, Mauritius, Cambodia and China — which may adversely impact operating margin, product availability and supply chain operations.
“As of the date of this report a number of tariffs remain in effect, including significant tariffs between the U.S. and countries from which we obtain significant supply, such as Vietnam, Mauritius, Cambodia, and China.”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch